Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
19 - Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 172 - 177Publisher: Cambridge University PressPrint publication year: 2016
References
Falanga, A, Marchetti, M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014;40(3):348–58.Google ScholarPubMed
De Stefano, V, Za, T, Rossi, E, Vannucchi, AM, Ruggeri, M, Elli, E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93(3):372–80.CrossRefGoogle ScholarPubMed
Ellis, MH, Lavi, N, Vannucchi, A, Harrison, C. Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey. Thromb Res. 2014;134(2):251–4.CrossRefGoogle ScholarPubMed
Tefferi, A, Rumi, E, Finazzi, G, Gisslinger, H, Vannucchi, AM, Rodeghiero, F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–81.CrossRefGoogle ScholarPubMed
Scherber, R, Dueck, AC, Johansson, P, Barbui, T, Barosi, G, Vannucchi, AM, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–8.CrossRefGoogle ScholarPubMed
Michiels, JJ, Berneman, Z, Schroyens, W, Koudstaal, PJ, Lindemans, J, Neumann, HA, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets. 2006;17(8):528–44.CrossRefGoogle ScholarPubMed
Pascale, S, Petrucci, G, Dragani, A, Habib, A, Zaccardi, F, Pagliaccia, F, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012;119(15):3595–603.CrossRefGoogle ScholarPubMed
Smalberg, JH, Arends, LR, Valla, DC, Kiladjian, JJ, Janssen, HL, Leebeek, FW. Myeloproliferative neoplasms in Budd–Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120(25):4921–8.CrossRefGoogle ScholarPubMed
Stein, BL, Saraf, S, Sobol, U, Halpern, A, Shammo, J, Rondelli, D, et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013;54(9):1989–95.CrossRefGoogle ScholarPubMed
Aird, WC. Vascular bed-specific thrombosis. J Thromb Haemost. 2007;5(Suppl. 1):283–91.CrossRefGoogle ScholarPubMed
Sozer, S, Fiel, MI, Schiano, T, Xu, M, Mascarenhas, J, Hoffman, R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd–Chiari syndrome. Blood. 2009;113(21):5246–9.CrossRefGoogle ScholarPubMed
Kiladjian, JJ, Cervantes, F, Leebeek, FW, Marzac, C, Cassinat, B, Chevret, S, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111(10):4922–9.CrossRefGoogle ScholarPubMed
Barbui, T, Barosi, G, Birgegard, G, Cervantes, F, Finazzi, G, Griesshammer, M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70.CrossRefGoogle ScholarPubMed
Sekhar, M, Qi, X, Betti, S, Rossi, E. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost. 2015;115(1): Epub ahead of print.Google Scholar
De Stefano, V, McVinnie, K, Burroughs, AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol. 2013;162(6):730–47.Google Scholar
Pieri, L, Paoli, C, Guglielmelli, P, Fjerza, R, Arena, U, Marra, F, et al. (eds). A phase 2 study of ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasm. preliminary results. Blood. 2013;122(21).Google Scholar
Dentali, F, Ageno, W, Rumi, E, Casetti, I, Poli, D, Scoditti, U, et al. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. Thromb Res. 2014;134(1):41–3.CrossRefGoogle ScholarPubMed
Abel, GA, DeAngelo, DJ, Connors, JM, Sholl, LM, McCaffrey, RP, Longtine, JA. Clinical JAK2V617F mutation testing: limited utility for general hospital patients with venous and arterial thromboses in common locations. Am J Hematol. 2008;83(6):519–20.CrossRefGoogle ScholarPubMed
Barbui, T, Thiele, J, Passamonti, F, Rumi, E, Boveri, E, Ruggeri, M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179–84.CrossRefGoogle ScholarPubMed
Finazzi, G, Carobbio, A, Thiele, J, Passamonti, F, Rumi, E, Ruggeri, M, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26(4):716–19.CrossRefGoogle ScholarPubMed
Saposnik, G, Barinagarrementeria, F, Brown, RD, Jr., Bushnell, CD, Cucchiara, B, Cushman, M, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158–92.CrossRefGoogle ScholarPubMed